IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023

~ INB-100 treatment has achieved durable 100% complete remission (CR) in treated patients, including high-risk acute myeloid leukemia (AML) patients and a patient with acute lymphoblastic leukemia (ALL) who had failed 4 prior lines of therapy, including CAR-T, with all evaluable patients remaining alive at last assessment and one patient out beyond 3 years. ~ The latest data shows that allogeneic gamma-delta T cell expansion and persistence continued up to 180 days post-treatment, marking the first-ever demonstration of this type of response in an allogeneic cellular therapy. ~ With its generally favorable safety profile and evidence of gamma-delta T cell expansion, Dose Level 2 has been selected as the recommended Phase 2 dose (RP2D) for further cohort expansion. ~ The company will be holding a conference call at 10:00 a.m. ET today to discuss the latest clinical updates and data.